Brief: Vyne Therapeutics Announces Topline Results From Phase 2B Trial With Repibresib Gel In Nonsegmental Vitiligo
30/07/2025 13:48
July 30 (Reuters) - Vyne Therapeutics Inc VYNE.O: VYNE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM PHASE 2B TRIAL WITH REPIBRESIB GEL IN NONSEGMENTAL VITILIGO VYNE THERAPEUTICS INC - TRIAL DID NOT MEET PRIMARY ENDPOINT OR KEY SECONDARY ENDPOINT OF F-VASI50 AND F-VASI75 VYNE THERAPEUTICS INC - WILL TERMINATE EXTENSION PHASE OF TRIAL AND SEEK EXTERNAL PARTNER FOR CONTINUED DEVELOPMENT OF REPIBRESIB VYNE THERAPEUTICS INC - TO DISCONTINUE TREATMENT AND TERMINATE TRIAL Source text: ID:nGNX92ZjsX Further company coverage: VYNE.O ((Reuters.Briefs@thomsonreuters.com;))